ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Shi, Yuankai*; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, Chuan吉林大学; 南通大学; 哈尔滨医科大学; 中国医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1
Lancet Respiratory Medicine2022-11DOI: 10.1016/S2213-2600(22)00168-0
45被引22阅读
引用收藏
分享

学科与关键词

关键词
OPEN-LABELASIAN PATIENTSADVANCED NSCLCTKI THERAPYADENOCARCINOMARESISTANCEERLOTINIBAFATINIBOSIMERTINIBQLQ-C30
相关
加载中…
  • Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)
    Shi, Y-K.; Chen, G.; Wang, X.; Liu, Y.; Wu, L.; Hao, Y.; Liu, C.; Zhu, S.; Zhang, X.; Li, Y.; Liu, J.; Cao, L.; Cheng, Y.; Zhao, H.; Zhang, S.; Zang, A.; Cui, J.; Feng, J.; Liu, F.; Gu, C.被引 3
  • Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study
    Shi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Ai-min; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
    Shi, Yuankai*; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, ChuanJournal of Thoracic Oncology, 2022, 17(11): 1297-1305.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
Lancet Respiratory Medicine
发表日期
2022-11
卷期
第 10 卷, 第 11 期
页码
1019-1028
DOI
10.1016/S2213-2600(22)00168-0
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
China National Major Project for New Drug Innovation

作者

  • S

    Shi, Yuankai (通讯) (第一作者)

    chinese acad med sci · peking union med coll

  • C

    Chen, Gongyan

    harbin med univ

查看全部 22 位作者收起作者
  • W

    Wang, Xiang

  • L

    Liu, Yunpeng

    1 · china med univ

  • W

    Wu, Lin

    2 · hunan canc hosp

  • H

    Hao, Yanrong

    peoples hosp guangxi zhuang autonomous reg

  • L

    Liu, Chunling

    xinjiang med univ

  • Z

    Zhu, Shuyang

    xuzhou med coll

  • Z

    Zhang, Xiaodong

    nantong canc hosp

  • L

    Li, Yuping

    1 · wenzhou med univ

  • L

    Liu, Jiwei

    1 · dalian med univ

  • C

    Cao, Lejie

    1 · ustc

  • C

    Cheng, Ying

  • Z

    Zhao, Hui

    2 · anhui univ

  • Z

    Zhang, Shucai

    beijing chest hosp · capital med univ

  • Z

    Zang, Aimin

    hebei univ

  • C

    Cui, Jiuwei

    jilin univ

  • F

    Feng, Jian

    nantong univ

  • Y

    Yang, Nong

    hunan canc hosp

  • L

    Liu, Fei

  • J

    Jiang, Yong

  • G

    Gu, Chuan

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417